Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

tion: the company's dependence on the success of its only two product candidates; additional ongoing or planned clinical trials of Acetavance or Omigard conducted by the company may produce negative or inconclusive results, or may be inconsistent with clinical trials previously conducted by Cadence, its licensors or others; delays in completing Cadence's clinical trials or achieving its product development goals, or significant issues regarding the results, design or execution of its clinical trials; the potential need or requirement to expand or modify the company's ongoing clinical trials or to conduct additional clinical trials; the market potential for Cadence's product candidates, and its ability to compete with new or existing products; unanticipated adverse side effects or inadequate therapeutic efficacy of the company's product candidates; delays or quality issues with respect to completion of pre-commercialization manufacturing development activities; other difficulties or delays in developing, testing, manufacturing, obtaining regulatory approval for, and marketing Cadence's product candidates; the scope, validity and limitations in the company's patent rights, and its ability to maintain patent protection for its product candidates; the need to obtain substantial additional funding to complete the company's clinical development programs and successfully launch its products, and the potential that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after th
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... In a new study conducted at a ... that shoulder pain was their first mesothelioma symptom. Surviving Mesothelioma ... Click here to read it now. , Doctors at ... of 49 mesothelioma patients between 2006 and 2012 ... shoulder pain that first prompted them to see a doctor. ...
(Date:3/6/2015)... The Gluten-Free Certification Program (GFCP), ... pleased to announce that Dufflet Pastries, the ground-breaking ... their product line of gluten-free treats certified by ... as satisfying as any of their other desserts! ... contains hydrogenated fats or oils, artificial flavours, colours ...
(Date:3/6/2015)... FCPX developers have announced a new ... “Pro3rd Hue is a lower 3rd pack with a clean ... Studios. “Blurring the line between professional and armature, Pro3rd Hue ... set of 30 customizable lower third presets made exclusively for ... users can complement any design with a clean and simplistic ...
(Date:3/6/2015)... FL (PRWEB) March 06, 2015 The producers ... March 2015 air dates for Spokane, Washington and vicinity. This ... places to shop and dine, and many outdoor activities. It ... supporting the local economy. Six major hospitals call the city ... the Canadian border. The medically-focused cable TV program will be ...
(Date:3/6/2015)... 2015 Fluid Running® Owner, Jennifer Conroyd, ... the Fluid Running® method 3 years ago ... marathon. She hit upon the trifecta of combining matched-bpm ... a maximum-resistance, deep water running technique. She not only ... water running workout that made the experience both enjoyable ...
Breaking Medicine News(10 mins):Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3
... Most U.S. states are poorly prepared to deal with a ... in Japan, suggests a survey of state health departments. ... (76 percent) of state health departments responded to the [2010] ... plants." The findings were published online March 14 in ...
... 2011Since the first laparoscopic procedure was performed to remove ... in St. Louis, this breakthrough minimally invasive technique has ... remarkable achievement is celebrated with a series of cutting-edge ... journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ...
... Montreal, March 15, 2011 The Montreal Heart ... 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis ... coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, ... therapies to treat cardiovascular and metabolic diseases. ...
... University of the Negev (BGU) researchers have shown that a ... have Obstructive Sleep Apnea (OSA), which may be the reason ... compared men between the ages of 55 and 75 who ... and reported nocturia at least once nightly. The comparison control ...
... amount of data created by today,s high throughput DNA ... the globe. How to handle the staggering amount of ... questions that initiated the experiment? Aside from the cost ... are being spent worldwide to expand hardware and storage ...
... (BCS) results from hepatic venous outflow obstruction,at any ... Few patients respond to,medical treatment (anticoagulation thrombolytic ... restore the hepatic blood flow. Restoring outflow in ... dilatation stenting is the management of choice. ...
Cached Medicine News:Health News:U.S. Unprepared for Major Radiation Emergency: Survey 2Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Potential new treatment to reduce the burden of atherosclerosis in acute coronary syndrome patients 2Health News:mygenomatix: A secure cloud-like model for next-gen sequencing data analysis 2
(Date:3/5/2015)... Germany , March 5, 2015 ... today announced that the foundation has made a ... CureVac, a leading clinical-stage biopharmaceutical company specializing in ... the foundation will also provide separate funding for ... CureVac,s proprietary messenger RNA (mRNA) platform. In addition, ...
(Date:3/5/2015)... , March 5, 2015  Sanomedics, Inc. (OTC: SIMH, ... company focused on developing, manufacturing, and acquiring cutting-edge technology, ... Thermomedics, Inc., will be exhibiting at booth # 709 ... Conference (NAPNAP) taking place on March 11-13, 2015 ... The 36 th ...
(Date:3/5/2015)... N.Y. , March 5, 2015  AMRI (NASDAQ: ... Pettersson , fills the newly created position of VP ... Christopher Conway , Senior Vice President of Global Sales ... Pettersson will lead the international sales team in an ... share in targeted market segments. Mr. Pettersson will drive ...
Breaking Medicine Technology:The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3AMRI Hires VP of International Sales 2
... , June 30 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ("Concord ... network of radiotherapy and diagnostic imaging centers in China ,today announced ... , , ... the program, Concord Medical is authorized to repurchase up to US$20,million ...
... DIEGO , June 30 ADVENTRX Pharmaceuticals, Inc. (NYSE ... performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured ... are on track to support the submission of a New Drug ... , , ...
Cached Medicine Technology:Concord Medical Announces Share Repurchase Program 2Concord Medical Announces Share Repurchase Program 3ADVENTRX Announces 9-Month Stability Data Results for ANX-530 2ADVENTRX Announces 9-Month Stability Data Results for ANX-530 3
Lyphochek Hemostasis Control is a multi-analyte control to help monitor coagulation factor assays and selected thrombosis risk assays. Assayed values are available for most major instrumentation....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
Medicine Products: